| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00439-018-1944-6 |
| P698 | PubMed publication ID | 30328515 |
| P50 | author | Steven A. Narod | Q50384888 |
| P2860 | cites work | Genome-wide association study identifies novel breast cancer susceptibility loci | Q24645441 |
| Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| The landscape of cancer genes and mutational processes in breast cancer | Q29614637 | ||
| A new initiative on precision medicine | Q29615654 | ||
| Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. | Q30238753 | ||
| Inherited Mutations in Women With Ovarian Carcinoma | Q30353433 | ||
| Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study | Q30415050 | ||
| High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing | Q30514084 | ||
| Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. | Q30826387 | ||
| Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls | Q31147531 | ||
| Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation | Q33633402 | ||
| International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers | Q34116505 | ||
| Effect of three decades of screening mammography on breast-cancer incidence | Q34313044 | ||
| Abolishing mammography screening programs? A view from the Swiss Medical Board. | Q34415457 | ||
| Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. | Q34436508 | ||
| Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study | Q34783837 | ||
| Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome | Q34901055 | ||
| CYP2D6 and tamoxifen: DNA matters in breast cancer | Q34993830 | ||
| Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers | Q35690548 | ||
| Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ | Q35812120 | ||
| Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. | Q36258270 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial | Q36634556 | ||
| Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers | Q37122297 | ||
| Evaluation of ultra-deep targeted sequencing for personalized breast cancer care | Q37690220 | ||
| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial | Q38581287 | ||
| Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer | Q38622172 | ||
| Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment | Q38669803 | ||
| The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania | Q38809495 | ||
| Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment | Q38838757 | ||
| NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. | Q39045746 | ||
| Tamoxifen Chemoprevention--End of the Road? | Q41509657 | ||
| Preventing ovarian cancer through genetic testing: a population-based study | Q43574918 | ||
| Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers | Q44256039 | ||
| Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer | Q44323635 | ||
| Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis | Q44490673 | ||
| Association analysis identifies 65 new breast cancer risk loci. | Q45979098 | ||
| The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation | Q46542512 | ||
| Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update | Q46838391 | ||
| Is invasion a necessary step for metastases in breast cancer? | Q49898559 | ||
| Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. | Q49990093 | ||
| Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). | Q50724452 | ||
| The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. | Q52564354 | ||
| Consolidated principles for screening based on a systematic review and consensus process. | Q54968873 | ||
| Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women | Q56900447 | ||
| Precision Medicine Meets Public Health: Population Screening for BRCA1 and BRCA2 | Q57499876 | ||
| Beyond odds ratios — communicating disease risk based on genetic profiles | Q58047301 | ||
| Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades | Q61830113 | ||
| Cancer incidence in five continents. Volume VIII | Q73541404 | ||
| Rethink on screening for breast cancer | Q73699589 | ||
| Polygenic susceptibility to breast cancer and implications for prevention | Q78029012 | ||
| Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy | Q78378112 | ||
| Direct-to-patient BRCA1 testing: the Twoj Styl experience | Q79811213 | ||
| Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer | Q83419012 | ||
| Aspirin in prevention of ovarian cancer: are we at the tipping point? | Q87245430 | ||
| Contemporary Hormonal Contraception and the Risk of Breast Cancer | Q88202128 | ||
| Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation | Q88791860 | ||
| Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer | Q88816510 | ||
| Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study | Q89765536 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 769-778 | |
| P577 | publication date | 2018-10-17 | |
| P1433 | published in | Human Genetics | Q5937167 |
| P1476 | title | Personalised medicine and population health: breast and ovarian cancer | |
| P478 | volume | 137 |
| Q92916923 | Breast Cancer Statistics: Recent Trends |
| Q89746441 | Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field |
| Q98386430 | Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism |
Search more.